Huan-Ling Zhu (Huanling Zhu)

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Venues

American journal of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis. American journal of hematology 99 (4) (2024)
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis. American journal of hematology (2024)
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis. American journal of hematology 99 (4) (2024)
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Hewen Yin, Shanshan Suo, Wenjuan Yu, Jie Jin
Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis. American journal of hematology 99 (4) (2024)
Yi Zhang, Hu Zhou, Ming-Hui Duan, Sujun Gao, Guang-Sheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huan-Ling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei Wang, Na Xu, Haiping Yang, Binhua Lu, Hewen Yin, Liqing Wu, Shanshan Suo, Qingwei Zhao, Zhijian Xiao, Jie Jin
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. American journal of hematology (2023)
Sen Yang, Xiaoshuai Zhang, Robert Peter Gale, Xin Du, Chun-Yan Chen, Jian-Yu Weng, Jian Huang, Fei Li, Yun Zeng, Zhen Xiao, Jian-da Hu, Li-Jie Yang, Zhuo-Gang Liu, Guo-Hui Li, Xiu-Li Sun, Wei Yang, Ru Feng, Yan-Qiu Han, Yu Jing, Na Xu, Xiao-Li Liu, Zhen-Fang Liu, Xiao-Dong Wang, Shi-Xin Wu, Rong Liang, Yan-Li Zhang, Yun-Fan Yang, Huan-Ling Zhu, Ling Pan, Li Meng, Yan-Hong Zhao, Hai Yi, Yi-Lan Liu, Wei-Hua Zhang, Yuan-Jun Zheng, Ze-Ping Zhou, Su-Ning Chen, Hui-Ying Qiu, Wei-Ming Li, Zhi-Lin Jia, Yan-Liang Bai, Li-E Lin, Bing-Cheng Liu, Chun-Shui Liu, Jian-Min Luo, Jun-Xia Meng, Zhi-Qiang Sun, Yan-Qing Zhang, Xiao-Jun Huang, Qian Jiang
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. American journal of hematology (2023)
Yi Zhang, Hu Zhou, Zhongxing Jiang, Dengshu Wu, Junling Zhuang, Wei Li, Qian Jiang, Xiuli Wang, Jinwen Huang, Huan-Ling Zhu, Linhua Yang, Xin Du, Fei Li, Ruixiang Xia, Feng Zhang, Jian-da Hu, Yan Li, Han Yan, Jing Liu, Chenghao Jin, Kai Sun, Zeping Zhou, Liqing Wu, Wenjuan Yu, Jie Jin
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial. American journal of hematology 97 (12) (2022)

Huan-Ling Zhu.css-eqlu8i{font-size:small;padding-left:4px;} (Huanling Zhu)

Publication Activity (10 Years)

Top Topics

Top Venues

Huan-Ling Zhu (Huanling Zhu)